Literature DB >> 7833133

Dysplasia in normal-looking urothelium increases the risk of tumour progression in primary superficial bladder cancer.

L A Kiemeney1, J A Witjes, R P Heijbroek, F M Debruyne, A L Verbeek.   

Abstract

Random urothelium biopsies were taken at initial endoscopic surgery from 1001 patients with primary superficial bladder cancer. The clinical course of all the patients was assessed prospectively. Actuarial risks of recurrence and disease progression were determined for prognostic characteristics and comparisons were made using log-rank tests. The independent prognostic significance of concomitant intra-aurothelial dysplastic changes was examined with Cox's regression analyses. The 3-year risk of recurrence in patients with dysplasia and carcinoma in situ (CIS) in macroscopically normal-looking urothelium was only slightly higher than the risk in patients without dysplastic changes (56, 58 and 51%, respectively; P = 0.25). Concomitant dysplasia or CIS significantly increased the 3-year risk of disease progression (17 and 31%, respectively, versus 7%; P < 0.001). After adjustment for the effects of age, tumour stage, grade, size and multicentricity, the result of random biopsies had no prognostic significance regarding the risk of recurrence, but the detection of dysplasia or CIS increased the risk of progression by approximately 80%. This result suggests that random urothelium biopsies may be useful as an additional guide in defining therapy in primary superficial bladder cancer.

Entities:  

Mesh:

Year:  1994        PMID: 7833133     DOI: 10.1016/0959-8049(94)e0133-o

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

Review 1.  Biomarkers as surrogates for cancer development.

Authors:  E Hawk; J L Viner; J A Lawrence
Journal:  Curr Oncol Rep       Date:  2000-05       Impact factor: 5.075

2.  Early detection of urothelial premalignant lesions using hexaminolevulinate fluorescence cystoscopy in high risk patients.

Authors:  Salvatore Blanco; Marco Raber; Biagio Eugenio Leone; Luca Nespoli; Marco Grasso
Journal:  J Transl Med       Date:  2010-11-22       Impact factor: 5.531

3.  Bladder cancer: Normal cystoscopy, malignant cytology in NMIBC: why biopsy?

Authors:  Antonio Lopez-Beltran
Journal:  Nat Rev Urol       Date:  2014-08-26       Impact factor: 14.432

4.  Update on the management of non-muscle invasive bladder cancer.

Authors:  Saad Aldousari; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2010-02       Impact factor: 1.862

5.  Clinical impact of bladder biopsies with TUR-BT according to cytology results in patients with bladder cancer: a case control study.

Authors:  Masashi Matsushima; Eiji Kikuchi; Masanori Hasegawa; Kazuhiro Matsumoto; Akira Miyajima; Mototsugu Oya
Journal:  BMC Urol       Date:  2010-06-30       Impact factor: 2.264

6.  Biopsies of the normal-appearing urothelium in primary bladder cancer.

Authors:  Davor Librenjak; Zana Saratlija Novakovic; Marijan Situm; Kazimir Milostic; Mario Duvnjak
Journal:  Urol Ann       Date:  2010-05

7.  Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history.

Authors:  Erik Pasin; David Y Josephson; Anirban P Mitra; Richard J Cote; John P Stein
Journal:  Rev Urol       Date:  2008

8.  The significance of random bladder biopsies in superficial bladder cancer.

Authors:  Cağatay Göğüş; Yaar Bedük; Kadir Türkölmez; Orhan Göğüs
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

9.  Pathobiology and chemoprevention of bladder cancer.

Authors:  Takuji Tanaka; Katsuhito Miyazawa; Tetsuya Tsukamoto; Toshiya Kuno; Koji Suzuki
Journal:  J Oncol       Date:  2011-09-15       Impact factor: 4.375

10.  Bladder carcinoma data with clinical risk factors and molecular markers: a cluster analysis.

Authors:  Enrique Redondo-Gonzalez; Leandro Nunes de Castro; Jesús Moreno-Sierra; María Luisa Maestro de las Casas; Vicente Vera-Gonzalez; Daniel Gomes Ferrari; Juan Manuel Corchado
Journal:  Biomed Res Int       Date:  2015-03-19       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.